Acute Severe Ulcerative Colitis: Optimal Strategies for Drug Therapy

키워드

참고문헌 (67)

1. Baumgart DC, "Inflammatory bowel disease : clinical aspects and established and evolving therapies", Lancet, 369, pp.1641~1657 (2007)
2. Nakase H, "The influence of cytokines on the complex pathology of ulcerative colitis", Autoimmun Rev, 21, pp.103017~ (2022)
3. Nakase H, "Evidence-based clinical practice guidelines for inflammatory bowel disease 2020", J Gastroenterol, 56, pp.489~526 (2021)
4. Dinesen LC, "The pattern and outcome of acute severe colitis", J Crohns Colitis, 4, pp.431~437 (2010)
5. Aratari A, "Colectomy rate in acute severe ulcerative colitis in the infliximab era", Dig Liver Dis, 40, pp.821~826 (2008)
6. Lynch RW, "Outcomes of rescue therapy in acute severe ulcerative colitis : data from the United Kingdom inflammatory bowel disease audit", Aliment Pharmacol Ther, 38, pp.935~945 (2013)
7. Jain S, "Predictors of long-term outcomes in patients with acute severe colitis : a northern Indian cohort study", J Gastroenterol Hepatol, 33, pp.615~622 (2018)
8. Lee HS, "Short-and long-term outcomes of acute severe ulcerative colitis in Korea : the 1999-2005 cohort", Inflamm Bowel Dis, 21, pp.1825~1831 (2015)
9. Festa S, "Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era : a multicentre cohort study", United European Gastroenterol J, 9, pp.507~516 (2021)
10. Feuerstein JD, "AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis", Gastroenterology, 158, pp.1450~1461 (2020)
11. Harbord M, "Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2 : current management", J Crohns Colitis, 11, pp.769~784 (2017)
12. Lamb CA, "British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults", Gut, 68(Suppl 3), pp.s1~s106 (2019)
13. Truelove SC, "Cortisone in ulcerative colitis; final report on a therapeutic trial", Br Med J, 2, pp.1041~1048 (1955)
14. Torres J, "Predicting outcomes to optimize disease management in inflammatory bowel diseases", J Crohns Colitis, 10, pp.1385~1394 (2016)
15. Hindryckx P, "Acute severe ulcerative colitis : from pathophysiology to clinical management", Nat Rev Gastroenterol Hepatol, 13, pp.654~664 (2016)
16. Gisbert JP, "Acute severe ulcerative colitis : state of the art treatment", Best Pract Res Clin Gastroenterol, 32-33, pp.59~69 (2018)
17. Issa M, "Impact of Clostridium difficile on inflammatory bowel disease", Clin Gastroenterol Hepatol, 5, pp.345~351 (2007)
18. Ananthakrishnan AN, "Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease", Gut, 57, pp.205~210 (2008)
19. Nguyen GC, "A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients", Am J Gastroenterol, 103, pp.1443~1450 (2008)
20. McCurdy JD, "A model for identifying cytomegalovirus in patients with inflammatory bowel disease", Clin Gastroenterol Hepatol, 13, pp.131~137 (2015)
21. Travis SP, "Predicting outcome in severe ulcerative colitis", Gut, 38, pp.905~910 (1996)
22. Ho GT, "Predicting the outcome of severe ulcerative colitis : development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery", Aliment Pharmacol Ther, 19, pp.1079~1087 (2004)
23. Lindgren SC, "Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis", Eur J Gastroenterol Hepatol, 10, pp.831~835 (1998)
24. Seo M, "Evaluation of disease activity in patients with moderately active ulcerative colitis : comparisons between a new activity index and Truelove and Witts’ classification", Am J Gastroenterol, 90, pp.1759~1763 (1995)
25. Jain S, "Faecal calprotectin and UCEIS predict short-term outcomes in acute severe colitis : prospective cohort study", J Crohns Colitis, 11, pp.1309~1316 (2017)
26. Kaplan GG, "Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis", Gastroenterology, 134, pp.680~687 (2008)
27. Lichtiger S, "Cyclosporine in severe ulcerative colitis refractory to steroid therapy", N Engl J Med, 330, pp.1841~1845 (1994)
28. Cohen RD, "Intravenous cyclosporin in ulcerative colitis : a five-year experience", Am J Gastroenterol, 94, pp.1587~1592 (1999)
29. Cohen RD, "A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin", Inflamm Bowel Dis, 5, pp.1~10 (1999)
30. Moskovitz DN, "Incidence of colectomy during long-term follow-up after cyclosporineinduced remission of severe ulcerative colitis", Clin Gastroenterol Hepatol, 4, pp.760~765 (2006)
31. Kobayashi T, "Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis", J Gastroenterol, 45, pp.1129~1137 (2010)
32. Komaki Y, "Efficacy and safety of tacrolimus therapy for active ulcerative colitis; a systematic review and meta-analysis", J Crohns Colitis, 10, pp.484~494 (2016)
33. Ogata H, "A randomised dose finding study of oral tacrolimus(FK506)therapy in refractory ulcerative colitis", Gut, 55, pp.1255~1262 (2006)
34. Yamamoto S, "Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis", Aliment Pharmacol Ther, 28, pp.589~597 (2008)
35. Ogata H, "Double-blind, placebo-controlled trial of oral tacrolimus(FK506)in the management of hospitalized patients with steroid-refractory ulcerative colitis", Inflamm Bowel Dis, 18, pp.803~808 (2012)
36. Schmidt KJ, "Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis : experience in 130 patients", Aliment Pharmacol Ther, 37, pp.129~136 (2013)
37. Miyoshi J, "Mucosal healing with oral tacrolimus is associated with favorable medium-and long-term prognosis in steroid-refractory", dependent ulcerative colitis patients, 2013, pp.7, e609~e614
38. Rosen MJ, "Review article : applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis", Aliment Pharmacol Ther, 41, pp.1094~1103 (2015)
39. Laharie D, "Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids : a parallel, open-label randomised controlled trial", Lancet, 380, pp.1909~1915 (2012)
40. Laharie D, "Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab", Gut, 67, pp.237~243 (2018)
41. Minami N, "Tacrolimus or infliximab for severe ulcerative colitis : short-term and longterm data from a retrospective observational study", BMJ Open Gastroenterol, 2, pp.e000021~ (2015)
42. Komaki Y, "Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis : a network meta-analysis", J Gastroenterol Hepatol, 32, pp.1143~1151 (2017)
43. Brandse JF, "Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis", Gastroenterology, 149, pp.350~355 (2015)
44. Ungar B, "Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis", Aliment Pharmacol Ther, 43, pp.1293~1299 (2016)
45. Hindryckx P, "Review article : dose optimisation of infliximab for acute severe ulcerative colitis", Aliment Pharmacol Ther, 45, pp.617~630 (2017)
46. Nalagatla N, "Effect of accelerated infliximab induction on short-and long-term outcomes of acute severe ulcerative colitis : a retrospective multicenter study and meta-analysis", Clin Gastroenterol Hepatol, 17, pp.502~509 (2019)
47. Herfarth HH, "Pushing the pedal to the metal : should we accelerate infliximab therapy for patients with severe ulcerative colitis?", Clin Gastroenterol Hepatol, 13, pp.336~338 (2015)
48. Järnerot G, "Infliximab as rescue therapy in severe to moderately severe ulcerative colitis : a randomized, placebo-controlled study", Gastroenterology, 128, pp.1805~1811 (2005)
49. Williams JG, "Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis(CONSTRUCT) : a mixed methods, open-label, pragmatic randomised trial", Lancet Gastroenterol Hepatol, 1, pp.15~24 (2016)
50. Narula N, "Systematic review : sequential rescue therapy in severe ulcerative colitis : do the benefits outweigh the risks?", Inflamm Bowel Dis, 21, pp.1683~1694 (2015)
51. Berinstein JA, "Efficacy of induction therapy with high-intensity tofacitinib in 4 patients with acute severe ulcerative colitis", Clin Gastroenterol Hepatol, 17, pp.988~990 (2019)
52. Berinstein JA, "Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis : a retrospective case-control study", Clin Gastroenterol Hepatol, 19, pp.2112~2120 (2021)
53. Kotwani P, "Tofacitinib for rescue therapy in acute severe ulcerative colitis : a real-world experience", J Crohns Colitis, 14, pp.1026~1028 (2020)
54. Gilmore R, "Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis", J Crohns Colitis, 16, pp.166~168 (2022)
55. Perry C, "Vedolizumab dose escalation improves therapeutic response in a subset of patients with ulcerative colitis", Dig Dis Sci, 66, pp.2051~2058 (2021)
56. Graziano F, "Rescue therapy with intensive vedolizumab optimization in a seventeen-year-old girl with acute severe ulcerative colitis", Dig Dis Sci, 66, pp.2470~2471 (2021)
57. Feagan BG, "Vedolizumab as induction and maintenance therapy for ulcerative colitis", N Engl J Med, 369, pp.699~710 (2013)
58. McIntyre PB, "Controlled trial of bowel rest in the treatment of severe acute colitis", Gut, 27, pp.481~485 (1986)
59. González-Huix F, "Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis", Am J Gastroenterol, 88, pp.227~232 (1993)
60. Miehsler W, "Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?", Gut, 53, pp.542~548 (2004)
61. Nguyen GC, "Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients", Am J Gastroenterol, 103, pp.2272~2280 (2008)
62. Ananthakrishnan AN, "Thromboprophylaxis is associated with reduced post-hospitalization venous thromboembolic events in patients with inflammatory bowel diseases", Clin Gastroenterol Hepatol, 12, pp.1905~1910 (2014)
63. Kornbluth A, "Ulcerative colitis practice guidelines in adults : American College of Gastroenterology, Practice Parameters Committee", Am J Gastroenterol, 105, pp.501~523 (2010)
64. Mowat C, "Guidelines for the management of inflammatory bowel disease in adults", Gut, 60, pp.571~607 (2011)
65. Dignass A, "Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2 : current management", J Crohns Colitis, 6, pp.991~1030 (2012)
66. Griffiths BJ, "Evaluation of global coagulation profiles in patients with acute severe colitis : implications for thromboprophylaxis", Gastroenterology, 148(4 Suppl 1), pp.S-133~ (2015)
67. Dolinger MT, "Dual biologic and small molecule therapy for the treatment of refractory pediatric inflammatory bowel disease", Inflamm Bowel Dis, 27, pp.1210~1214 (2021)

관련 논문AI추천